Lyra Therapeutics (NSDQ:LYRA) announced today that it entered into a strategic partnership with LianBio for its LYR-210 treatment for chronic rhinosinusitis. Watertown, Mass.–based Lyra, which develops the LYR-210 therapeutic to be locally delivered by its proprietary XTreo platform, could receive up to $135 million in total payments through the strategic partnership and exclusive license agreement […]
Funding Roundup
Giiant Pharma raises $11M for drug delivery platform for gastroenterology
Giiant Pharma announced today that it closed a $11 million seed financing round for its drug delivery technology platform. Montreal-based Giiant develops the Precision Delivery technology platform, which originated from the work of former Merck Frosst scientists, according to a news release. The company designs gut-restricted, tissue-specific, small-molecule drug therapeutics to be delivered through the […]
Interius BioTherapeutics raises $76M Series A
Interius BioTherapeutics announced today that it raised $76 million in an oversubscribed Series A financing round. Philadelphia-based Interius develops treatments for hematologic malignancies. The company’s novel gene delivery platform generates chimeric antigen receptor (CAR) T cells directly in vivo to bypass the need for ex vivo cell manipulations and the potentially toxic pre-conditioning chemotherapy required […]
Gyroscope Therapeutics launches IPO roadshow
Gyroscope Therapeutics announced today that it launched the roadshow for its initial public offering of nearly 7 million shares. London-based Gyroscope’s U.S. offering includes up to 6.75 million American Depository Shares (ADSs) representing 6.75 million ordinary shares, according to a news release. Gyroscope expects pricing for the IPO to range between $20 and $22 per […]
Valeo Pharma closes upsized $6.6M private placement
Valeo Pharma announced today that it closed an upsized private placement worth more than $6.6 million. Montreal, Canada-based Valeo issued 6,645 unsecured, non-convertible debenture units at a purchase price of $1,000 per unit, totaling gross proceeds of $6.645 million, according to a news release. Each debenture unit consists of one unsecured non-convertible debenture in the […]
Glytec raises $21M for insulin dosing management tech
Glytec announced today that it raised $21 million in financing to fund its glycemic management technology. Waltham, Mass.-based Glytec received $9 million in debt financing from Silicon Valley Bank, combined with $12 million in equity funding, led by Savitr with contribution from other private investors, according to a news release. The company said it plans […]
Code Biotherapeutics launches with $10M seed financing
Gene therapy developer Code Biotherapeutics announced today that it launched with $10 million in seed financing. Hatfield, Pa.-based Code Biotherapeutics develops 3DNA, a proprietary synthetic DNA-based vector designed to deliver genes of all sizes to multiple cell types as a re-dosable therapy, according to a news release. The company said it is focused on developing […]
Virta Health raises $133M Series E for diabetes reversal tech
Virta Health announced today that it raised $133 million in a Series E equity financing round led by Tiger Global. San Francisco-based Virta said in a news release that the funds will accelerate its efforts to drive the adoption of its telehealth-based diabetes reversal treatment that aims to reverse the chronic disease while removing the […]
CeQur raises $115M for wearable insulin delivery device
CeQur announced today that it closed an oversubscribed equity financing round with proceeds of $115 million. Lucerne, Switzerland/Marlborough, Mass.–based CeQur said in a news release that it plans to use the funds to advance the commercial plans for the CeQur Simplicity wearable insulin delivery device. The company’s plans include market development, a phased commercial launch […]
GH Research closes $125M oversubscribed Series B
GH Research Ireland announced that it closed an oversubscribed Series B financing round with proceeds of $125 million. Dublin, Ireland-based GH develops the GH001 therapeutic, a drug product for 5-MeO-DMT administration through a proprietary inhalation approach. A Phase 1 healthy volunteer trial showed GH001 to be well-tolerated while defining a dose range and individualized dosing […]
